Billionaire Profile
Ugur Sahin
Global Rank
#974

Image: BioNTech | CC BY-SA 4.0 | via Wikimedia Commons

Ugur Sahin

CEO, Biotechnology
GERMANY
Real-Time Net Worth
$4.385B
Estimated based on Biotechnology stock value as of April 20, 2026
0% (24h)
Age
60
Source
Biotechnology
Industry
Healthcare
Citizenship
GERMANY

Biography

Ugur Sahin, born in 1965, is a German medical researcher, entrepreneur, and businessman, and is currently ranked #908 on the Forbes Billionaires list. As the co-founder and CEO of BioNTech, Sahin has significantly impacted the biotechnology industry. His wealth source is rooted in biotechnology, specifically in the development of mRNA-based immunotherapies and vaccines. Sahin's career began in medicine, with a doctorate in cancer immunotherapy, and he later pursued research and academic roles before entering the entrepreneurial world. His most notable achievement is co-developing the first mRNA-based vaccine for COVID-19, with BioNTech's partner Pfizer. He also leads research on cancer vaccines. Sahin's pioneering work has led to several breakthroughs, earning him recognition and awards in the scientific community.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/20/2026

Wealth Over Time

In-Depth Profile

Early Life and Education

Ugur Sahin was born on September 19, 1965, in İskenderun, Turkey. At the age of four, he moved to Germany with his family, where his father worked in a Ford factory. Sahin excelled academically, graduating from the Erich-Kästner-Gymnasium in Cologne-Niehl in 1984. He pursued his medical studies at the University of Cologne from 1984 to 1992. During this time, he completed a doctoral thesis on immunotherapy against tumor cells, earning a summa cum laude. From 1992 to 1994, he studied mathematics at the Fernuniversität Hagen.

Rise to Success

Sahin's career includes impactful roles in both academia and industry. After his residency, he worked as a physician in internal medicine and hematology/oncology from 1991 to 2000 at the University Hospital of Cologne and then at the Saarland University Hospital in Homburg. In 1999, he habilitated in molecular medicine and immunology. In 2000, he joined the University Medical Center Mainz. Sahin co-founded Ganymed Pharmaceuticals in 2001 and later BioNTech in 2008 with his wife, Özlem Türeci, and Christoph Huber. BioNTech's collaboration with Pfizer to develop the COVID-19 vaccine was a pivotal moment, transforming the company and propelling Sahin into the global spotlight.

Key Business Strategies

Key business strategies include focusing on mRNA technology for cancer and infectious diseases. BioNTech's success is linked to its ability to translate scientific discoveries into life-saving treatments.

Philanthropy

Specific philanthropy amounts for Ugur Sahin could not be found; however, his charitable ethos has kept him grounded.

Career Milestones

2001

Co-founded Ganymed Pharmaceuticals

Founded with Özlem Türeci and Christoph Huber, focused on cancer treatments. Sold in 2016.

2008

Co-founded BioNTech

Co-founded with Özlem Türeci and Christoph Huber, focused on immunotherapies and vaccines.

2020

Developed COVID-19 Vaccine

Co-developed the first mRNA-based vaccine against COVID-19 in partnership with Pfizer.

Philanthropy & Social Impact

Not Available

Not Available

Undisclosed

No specific information about his philanthropy could be found.

Business Philosophy & Leadership

Notable Quotes

"I think the good message for mankind is that we now understand that COVID-19 infections can be indeed prevented by a vaccine"

Leadership Principles

Scientific Innovation

Pioneering new approaches to fight cancer and infectious diseases through mRNA technology.

Collaboration

Partnerships with pharmaceutical companies like Pfizer to develop and distribute vaccines.

Translational Research

Focusing on translating scientific discoveries into life-saving treatments.

Controversies & Challenges

Unknown

Not Available

No significant controversies found.